ISELIN, N.J., April 27 /PRNewswire-FirstCall/ -- Pharmos Corporation announced today that Pharmos President and Chief Operating Officer Alan Rubino gave an interview with the Wall Street Reporter, a Web-based media service. Replays of Mr. Rubino’s interview can be heard on demand at http://www.wallstreetreporter.com/profile.php?id=17629 for the next several days.
In the interview, Mr. Rubino highlighted recent corporate developments including the announced definitive agreement to acquire Vela Pharmaceuticals, a venture-capital backed, privately owned company, and Pharmos’ near-term business outlook.
About Pharmos Corporation
Pharmos discovers and develops novel therapeutics to treat a range of indications, including neurological and inflammatory disorders. The Company’s core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds. Cannabinor, the lead CB2-selective receptor agonist candidate, is scheduled for Phase II testing in pain indications during 2006. Other compounds from Pharmos’ proprietary synthetic cannabinoid library are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, and other disorders.
Statements made in this press release related to the business outlook and future financial performance of the Company, to the prospective market penetration of its drug products, to the development and commercialization of the Company’s pipeline products and to the Company’s expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties which may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos’ filings with the Securities and Exchange Commission could affect such results.
Pharmos Corporation
CONTACT: Gale Smith of Pharmos U.S., +1-732-452-9556, or John Quirk(investors), +1-646-536-7029, or Janine McCargo (media), +1-646-536-7033,both of The Ruth Group, Inc.
Web site: http://www.pharmoscorp.com/
